Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Scleroderma, Systemic | 4 | 2020 | 583 | 0.82 | Why? |
| Polymyositis | 1 | 2019 | 25 | 0.80 | Why? |
| Wnt Signaling Pathway | 1 | 2018 | 87 | 0.72 | Why? |
| Epigenomics | 1 | 2017 | 139 | 0.63 | Why? |
| Osteoarthritis | 1 | 2018 | 205 | 0.61 | Why? |
| Prostatic Neoplasms | 8 | 2019 | 1637 | 0.57 | Why? |
| Arthritis, Psoriatic | 1 | 2021 | 625 | 0.55 | Why? |
| Macrophages | 2 | 2020 | 2784 | 0.38 | Why? |
| Brachytherapy | 3 | 2018 | 93 | 0.36 | Why? |
| Carcinoma, Transitional Cell | 2 | 2019 | 198 | 0.32 | Why? |
| Arthritis | 2 | 2021 | 288 | 0.30 | Why? |
| Myositis | 2 | 2018 | 185 | 0.27 | Why? |
| Urologic Neoplasms | 2 | 2019 | 348 | 0.26 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1573 | 0.25 | Why? |
| Prostatectomy | 2 | 2017 | 485 | 0.23 | Why? |
| Urology | 3 | 2018 | 1685 | 0.20 | Why? |
| Neoplasm Recurrence, Local | 2 | 2018 | 1063 | 0.20 | Why? |
| Rheumatoid Factor | 1 | 2019 | 67 | 0.20 | Why? |
| DNA Viruses | 1 | 2021 | 184 | 0.19 | Why? |
| Wnt Proteins | 1 | 2018 | 38 | 0.19 | Why? |
| Serum Amyloid P-Component | 1 | 2020 | 193 | 0.19 | Why? |
| Cartilage, Articular | 1 | 2018 | 50 | 0.19 | Why? |
| Platinum Compounds | 1 | 2017 | 20 | 0.18 | Why? |
| beta Catenin | 1 | 2018 | 78 | 0.18 | Why? |
| Autoimmune Diseases | 3 | 2020 | 1996 | 0.18 | Why? |
| Platelet-Rich Plasma | 1 | 2018 | 91 | 0.18 | Why? |
| Ablation Techniques | 1 | 2018 | 54 | 0.17 | Why? |
| Kallikreins | 1 | 2018 | 158 | 0.17 | Why? |
| Acute-Phase Reaction | 1 | 2018 | 116 | 0.17 | Why? |
| Osteoporosis, Postmenopausal | 1 | 2018 | 75 | 0.17 | Why? |
| Prostate-Specific Antigen | 1 | 2018 | 213 | 0.17 | Why? |
| Diphosphonates | 1 | 2018 | 121 | 0.17 | Why? |
| High-Intensity Focused Ultrasound Ablation | 1 | 2016 | 19 | 0.17 | Why? |
| Janus Kinases | 1 | 2020 | 414 | 0.17 | Why? |
| Regenerative Medicine | 1 | 2018 | 161 | 0.16 | Why? |
| Cholangitis | 1 | 2017 | 81 | 0.16 | Why? |
| Testicular Neoplasms | 1 | 2017 | 91 | 0.16 | Why? |
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 106 | 0.16 | Why? |
| Cryosurgery | 1 | 2016 | 57 | 0.15 | Why? |
| Bone Density Conservation Agents | 1 | 2018 | 209 | 0.15 | Why? |
| Biological Therapy | 1 | 2020 | 456 | 0.15 | Why? |
| Watchful Waiting | 1 | 2017 | 276 | 0.15 | Why? |
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 317 | 0.14 | Why? |
| Lymph Node Excision | 1 | 2017 | 362 | 0.14 | Why? |
| Mitochondria | 2 | 2018 | 857 | 0.13 | Why? |
| Exercise Test | 1 | 2020 | 911 | 0.13 | Why? |
| Stakeholder Participation | 1 | 2017 | 481 | 0.13 | Why? |
| RNA Viruses | 1 | 2021 | 824 | 0.13 | Why? |
| Carcinoma | 1 | 2016 | 256 | 0.13 | Why? |
| Cardiac Catheterization | 1 | 2020 | 882 | 0.12 | Why? |
| Immunodominant Epitopes | 1 | 2017 | 813 | 0.12 | Why? |
| Androgen Antagonists | 1 | 2016 | 404 | 0.12 | Why? |
| Imidazoles | 1 | 2018 | 631 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.12 | Why? |
| Carcinoma, Renal Cell | 1 | 2018 | 545 | 0.12 | Why? |
| Radiotherapy | 1 | 2017 | 608 | 0.11 | Why? |
| Lung Injury | 1 | 2021 | 919 | 0.11 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.11 | Why? |
| Dendritic Cells | 1 | 2020 | 1330 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.11 | Why? |
| Interferons | 2 | 2021 | 2885 | 0.11 | Why? |
| Kidney Neoplasms | 1 | 2018 | 832 | 0.10 | Why? |
| Lymph Nodes | 1 | 2017 | 1060 | 0.10 | Why? |
| Evidence-Based Medicine | 3 | 2018 | 3228 | 0.10 | Why? |
| Gene Expression Profiling | 1 | 2020 | 3788 | 0.09 | Why? |
| Practice Guidelines as Topic | 3 | 2017 | 15421 | 0.09 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.09 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.09 | Why? |
| Rheumatology | 1 | 2018 | 1213 | 0.08 | Why? |
| Neoplasm Staging | 3 | 2018 | 1999 | 0.08 | Why? |
| Neoplasm Grading | 2 | 2017 | 400 | 0.07 | Why? |
| Immunotherapy | 1 | 2019 | 2421 | 0.07 | Why? |
| Infusions, Intravenous | 2 | 2020 | 1224 | 0.07 | Why? |
| Humans | 32 | 2021 | 930598 | 0.07 | Why? |
| Rheumatic Diseases | 1 | 2020 | 2675 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.07 | Why? |
| Virus Diseases | 1 | 2021 | 3779 | 0.06 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| Vitamin D | 1 | 2018 | 2904 | 0.06 | Why? |
| Medical Oncology | 1 | 2018 | 3826 | 0.06 | Why? |
| Disease-Free Survival | 2 | 2017 | 1654 | 0.06 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.06 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.06 | Why? |
| Sulfonamides | 2 | 2020 | 1294 | 0.05 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.05 | Why? |
| Male | 19 | 2021 | 367725 | 0.05 | Why? |
| Respiratory Tract Infections | 1 | 2021 | 6817 | 0.05 | Why? |
| Pulmonary Diffusing Capacity | 1 | 2020 | 191 | 0.05 | Why? |
| Poly I-C | 1 | 2020 | 176 | 0.05 | Why? |
| Carbon Monoxide | 1 | 2020 | 167 | 0.05 | Why? |
| Indazoles | 1 | 2018 | 77 | 0.05 | Why? |
| Consensus Development Conferences as Topic | 1 | 2018 | 93 | 0.05 | Why? |
| Echocardiography, Doppler | 1 | 2020 | 269 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.04 | Why? |
| Prognosis | 5 | 2020 | 32490 | 0.04 | Why? |
| Lymphoproliferative Disorders | 1 | 2019 | 110 | 0.04 | Why? |
| Macrophage Activation | 1 | 2020 | 315 | 0.04 | Why? |
| Bile Ducts | 1 | 2017 | 84 | 0.04 | Why? |
| Cryoglobulinemia | 1 | 2019 | 144 | 0.04 | Why? |
| Toll-Like Receptor 3 | 1 | 2020 | 391 | 0.04 | Why? |
| Tissue Extracts | 1 | 2016 | 9 | 0.04 | Why? |
| Pulmonary Gas Exchange | 1 | 2020 | 414 | 0.04 | Why? |
| Abiraterone Acetate | 1 | 2016 | 12 | 0.04 | Why? |
| Taxoids | 1 | 2016 | 45 | 0.04 | Why? |
| Autoantibodies | 2 | 2019 | 2094 | 0.04 | Why? |
| Breath Tests | 1 | 2020 | 338 | 0.04 | Why? |
| Immunoprecipitation | 1 | 2017 | 300 | 0.04 | Why? |
| Muscles | 1 | 2017 | 152 | 0.04 | Why? |
| Interleukin-1 | 1 | 2020 | 438 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Phenylthiohydantoin | 1 | 2016 | 87 | 0.04 | Why? |
| Neoadjuvant Therapy | 1 | 2019 | 554 | 0.04 | Why? |
| Death Certificates | 1 | 2017 | 130 | 0.04 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.04 | Why? |
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 109 | 0.04 | Why? |
| Superinfection | 1 | 2020 | 459 | 0.04 | Why? |
| Aged | 10 | 2021 | 215776 | 0.04 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.04 | Why? |
| Unnecessary Procedures | 1 | 2017 | 175 | 0.04 | Why? |
| Lung | 2 | 2021 | 31049 | 0.03 | Why? |
| A549 Cells | 1 | 2020 | 2066 | 0.03 | Why? |
| Lymphatic Metastasis | 1 | 2017 | 537 | 0.03 | Why? |
| Purines | 1 | 2020 | 816 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Survival Rate | 2 | 2018 | 9206 | 0.03 | Why? |
| Azetidines | 1 | 2020 | 722 | 0.03 | Why? |
| Salvage Therapy | 1 | 2016 | 417 | 0.03 | Why? |
| Hospitals, High-Volume | 1 | 2017 | 688 | 0.03 | Why? |
| Benzamides | 1 | 2016 | 421 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2020 | 9537 | 0.03 | Why? |
| Neoplasm Metastasis | 1 | 2016 | 682 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2020 | 1755 | 0.03 | Why? |
| Female | 11 | 2021 | 380317 | 0.03 | Why? |
| Benchmarking | 1 | 2017 | 627 | 0.03 | Why? |
| Cell Proliferation | 1 | 2020 | 1973 | 0.03 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.03 | Why? |
| Autoimmunity | 1 | 2019 | 841 | 0.03 | Why? |
| Protective Factors | 1 | 2018 | 1720 | 0.03 | Why? |
| Cell Line, Tumor | 1 | 2020 | 3608 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Quality Indicators, Health Care | 1 | 2017 | 580 | 0.03 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.03 | Why? |
| Nitriles | 1 | 2016 | 1053 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Respiratory Mucosa | 1 | 2020 | 1522 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.03 | Why? |
| Pyrimidines | 1 | 2018 | 1557 | 0.03 | Why? |
| Staphylococcal Infections | 1 | 2020 | 1099 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Europe | 2 | 2018 | 12702 | 0.03 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.03 | Why? |
| Endothelial Cells | 1 | 2020 | 2048 | 0.03 | Why? |
| Time Factors | 3 | 2017 | 31397 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.02 | Why? |
| Pyrazoles | 1 | 2020 | 1791 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2020 | 5542 | 0.02 | Why? |
| Cells, Cultured | 1 | 2020 | 5835 | 0.02 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2020 | 2654 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2020 | 2585 | 0.02 | Why? |
| Heart | 1 | 2018 | 1791 | 0.02 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.02 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.02 | Why? |
| Adult | 6 | 2021 | 244371 | 0.02 | Why? |
| Aged, 80 and over | 4 | 2018 | 88759 | 0.02 | Why? |
| Interferon Type I | 1 | 2020 | 2789 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.02 | Why? |
| Italy | 2 | 2021 | 38444 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.02 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Patient Safety | 1 | 2018 | 4885 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Signal Transduction | 1 | 2020 | 7207 | 0.02 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.02 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2019 | 5883 | 0.01 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.01 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.01 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.01 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.01 | Why? |
| France | 1 | 2017 | 12074 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Animals | 2 | 2020 | 78931 | 0.01 | Why? |
| Mice | 1 | 2020 | 21357 | 0.01 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.01 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.01 | Why? |
De Santis's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(224)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(152)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_